A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

632

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

April 30, 2010

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

IMVAMUNE

Subjects receiving two subcutaneous vaccinations

Trial Locations (22)

6760

Hospital General de México, Mexico City

14623

Dermatology Associates of Rochester, Rochester

45200

Hospital Angel Leañol, Dermatology, Zapopan, Jalisco

60611

Northwestern University, Chicago

63104

Saint Louis University, St Louis

63141

Sundance Clinical Research, St Louis

64460

"Centro Regional de Alergia e Inmunología Clínica del Hospital Universitario Dr. José Eleuterio González", Monterrey

66211

Adult & Pediatric Dermatology PC, Overland Park

68134

Meridian Clinical Research, Omaha

71913

Burke Pharmaceutical Research, Hot Springs

75230

Dermatology Treatment & Research Center, Dallas

78229

Dermatology Clinical Research, San Antonio

85745

Alta Clinical Research LLC, Tucson

92843

Rx Clinical Research, Inc., Garden Grove

94589

Solano Clinical Research, Vallejo

97210

Oregon Dermatology & Research Center, Portland

40536-0093

University of Kentucky Medical Center, Lexington

87106-5239

Academic Dermatology Associates, Albuquerque

07760

Hospital Juárez de México, Magdalena de las Salinas

Unknown

"Instituto Dermatologico de Jalisco Dr. Jose Barba Rubio", Guadalajara

CIFBIOTEC (Centro de Investigacion Farmacologica y Biotecnologica), Mexico City

Hospital Regional Lic. Adolfo Lopez Mateos. ISSSTE Ciudad de Mexico, Mexico City

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Bavarian Nordic

INDUSTRY

NCT00316602 - A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis | Biotech Hunter | Biotech Hunter